Cell Metabolism Features the AMP® Type 2 Diabetes Knowledge Portal as a Valuable Tool for Biomedical Researchers

NORTH BETHESDA, MD, April 4, 2023 — The Foundation for the National Institutes of Health (FNIH) announces that the Type 2 Diabetes Knowledge Portal (T2DKP) is featured in a Cell Metabolism article published today. The T2DKP is a publicly available source of genetic datasets dedicated to type 2 diabetes and its related traits.

The T2DKP is a result of the Accelerating Medicines Partnership® for Type 2 Diabetes (AMP T2D), a precompetitive public-private partnership convened by the FNIH with the National Institutes of Health, industry, and nonprofit organizations that harnessed collective partner capabilities, scale, and resources to prioritize drug development targets for diabetes and its complications. The AMP T2D Knowledge Portal provides software infrastructure to support, combine, and harmonize more than 300 anonymized datasets from research studies around the world. An innovative feature of the portal allows the retrieval of genetic data that complies with European Union data protection requirements. The Cell Metabolism article, with more than 50 authors that include FNIH’s David Wholley, Tania Kamphaus, and Lynette Nguyen, discusses the accessibility of the T2DKP data.

“[The portal] is effectively curated and, because it comes with a set of carefully developed analytic tools, it is immediately available to partner companies for their work in prioritizing targets, but it also provides a resource which can be used on an ongoing basis by the entire scientific community,” said David Wholley, Executive Vice President, Strategy and Business Development, at the FNIH. “That has tremendous value for patients long-term.”

The T2DKP is so successful that it has become the go-to source for researchers to deposit large amounts of data from studies related to the genetic associations of diabetes. It led directly to the establishment of the Common Metabolic Diseases Knowledge Portal, which aggregates data from the T2DKP and other cardiovascular, liver, and kidney conditions to enable the identification of drug development targets that will help patients with overlapping risk factors.

“That [T2D] Knowledge Portal has become a model for multiple other disease applications and has implications well beyond the study of this one disease,” said Francis Collins, MD, PhD, Former Director of the NIH.

The T2DKP was created by a multi-site team led by Noël Burtt and Jason Flannick at the Broad Institute of MIT and Harvard, Kyle Gaulton at the University of California San Diego, and Michael Boehnke at the University of Michigan. Additional partners in the T2DKP initiative included the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the American Diabetes Association, Eli Lilly and Company, Janssen Research and Development LLC, the Juvenile Diabetes Research Foundation, Merck, Pfizer Inc., and Sanofi. Learn more at https://fnih.org/our-programs/AMP/type-2-diabetes.

About the Foundation for the National Institutes of Health: The Foundation for the National Institutes of Health (FNIH) connects the world’s leading public and private organizations to accelerate biomedical breakthroughs for patients, regardless of who they are, where they live, or what disease they have. Together with leading scientists and problem-solvers, and a successful track record of navigating complex problems, the FNIH accelerates new therapies, diagnostics, and potential cures; advances global health and equity in care; and celebrates and trains the next generation of scientists. Established by Congress in 1990 to support the mission of the NIH, the FNIH is a not-for-profit 501(c)(3) charitable organization. For more information about the FNIH, please visit fnih.org.

Follow us on social media: LinkedIn, Twitter, Facebook


Melanie Doupé Gaiser
Ruder Finn, on behalf of FNIH
[email protected]

Back To News